Which Side Effects Should Be Described to Patients Before Neoadjuvant Radio-Chemotherapy Treatment?

  • Cynthia Aristei
  • Valentina Lancellotta
  • Marco Lupattelli


Chemotherapy and irradiation of organs adjacent to the target volumes are associated with significant acute gastrointestinal and genito-urinary toxicity and a high rate of post-operative complications and late toxicities. Assessing radiochemotherapy-related side-effects is hard because inter-study comparisons may be hampered by use of different toxicity scales, cohort sizes, study time-points, and study focus which may analyse, for example, only single side effects and their grades or all side-effects according to grade. Moreover, some side effects were under-analysed and under-reported. Finally, while increased early toxicity has been recognized in all trials, data are less clear about late toxicity. With the aim of improving the rectal cancer patient’s relationship with the radiation oncologist in the pre-treatment consultation this chapter answers the most common questions asked by a candidate for neo-adjuvant radio-chemotherapy.


  1. 1.
    Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933CrossRefPubMedGoogle Scholar
  2. 2.
    Gérard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625CrossRefPubMedGoogle Scholar
  3. 3.
    Bosset JF, Collette L, Calais G et al (2006) EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123Google Scholar
  4. 4.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72(1):15–24CrossRefPubMedGoogle Scholar
  5. 5.
    Roh MS, Colangelo LH, O’Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27(31):5124–5130CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in unresectable rectal cancer. J Clin Oncol 26(22):3687–3694CrossRefPubMedGoogle Scholar
  7. 7.
    Sainato A, Cernusco LNV, Valentini V et al (2014) No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113(2):223–229CrossRefPubMedGoogle Scholar
  8. 8.
    Appelt AL, Bentzen SM, Jakobsen A et al (2015) Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. Acta Oncol 54(2):179–186CrossRefPubMedGoogle Scholar
  9. 9.
    Wolff HA, Conradi LC, Schirmer M et al (2011) Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist 16(5):621–631CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579–588CrossRefPubMedGoogle Scholar
  11. 11.
    Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol 30(31):3827–3833CrossRefPubMedGoogle Scholar
  12. 12.
    François E, Azria D, Gourgou-Bourgade S et al (2014) Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol 110(1):144–149CrossRefPubMedGoogle Scholar
  13. 13.
    Martel G, Al-Suhaibani Y, Moloo H et al (2008) Neoadjuvant therapy and anastomotic leak after tumor-specific mesorectal excision for rectal cancer. Dis Colon Rectum 51(8):1195–1201Google Scholar
  14. 14.
    Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29(20):2773–2780CrossRefPubMedGoogle Scholar
  15. 15.
    An X, Lin X, Wang F-H et al (2013) Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer 49(4):843–851CrossRefPubMedGoogle Scholar
  16. 16.
    Valentini V, De Paoli A, Barba M.C. et al (2014) Capecitabine based preoperative chemo-RT in rectal cancer intensified by RT dose or oxaliplatin: the INTERACT trial. OC 0494, p 204, ESTRO 33, Vienna, 4–8 Apr 2014Google Scholar
  17. 17.
    Brændengen M, Tveit KM, Bruheim K et al (2011) Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys 81(4):1017–1024CrossRefPubMedGoogle Scholar
  18. 18.
    Coco C, Valentini V, Manno A et al (2007) Functional results after radiochemotherapy and total mesorectal excision for rectal cancer. Int J Color Dis 22(8):903–910CrossRefGoogle Scholar
  19. 19.
    Parekh A, Truong MT, Pashtan I et al (2013) Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointest Cancer Res 6(5–6):137–143PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Cynthia Aristei
    • 1
    • 2
  • Valentina Lancellotta
    • 1
    • 2
  • Marco Lupattelli
    • 3
  1. 1.Radiation Oncology SectionUniversity of PerugiaPerugiaItaly
  2. 2.Radiation Oncology DivisionPerugia General HospitalPerugiaItaly
  3. 3.Radiation Oncology DivisionPerugia General HospitalPerugiaItaly

Personalised recommendations